Sign inJoin waitlistJoin the waitlist

Marcia Brose

Emeritus Professor CE of Otorhinolaryngology: Head and Neck Surgery · University of Pennsylvania Health System

Credentials: · · · ·

History

University of Pennsylvania Health System
Present

Hospital of the University of Pennsylvania
1998–2000
Hospital of the University of Pennsylvania
1995–1998
The Rockefeller University
Cornell Univ Joan and Sanford I Weill Med Coll
1991–1995

Research

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
New England Journal of Medicine · 2018 · 2,193 citations
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer
New England Journal of Medicine · 2015 · 1,570 citations
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
The Lancet · 2014 · First of 18 authors · Corresponding · 1,247 citations

LW
Lori Wirth
19 papers
Matthew Taylor
14 papers
Steven Sherman
14 papers
AD
Alexander Drilon
9 papers
AH
Ana Hoff
8 papers
ES
Eric Sherman
8 papers
FW
Francis Worden
8 papers
Maria Cabanillas
8 papers
Michael Feldman
8 papers
Changqing Ma
7 papers
Daniel Bowles
7 papers
CA
Carol Aghajanian
6 papers

Grants

Brca1 Deletion in Murine Cells and Mammary Tissue
National Cancer Institute · K08
Contact PI · $689.3K · University of Pennsylvania
2003–2009

Clinical trials

UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone
Principal investigator · Suspended · Phase 2
Thomas Jefferson University
2017–2022
Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer
Principal investigator · Withdrawn · Phase 3
Mateon Therapeutics
2015–2017
A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
Principal investigator · Unknown · Phase 2
Thomas Jefferson University
2014–2022
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
Principal investigator · Unknown · Phase 2
Thomas Jefferson University
2010–2022